SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
Autonomous Cortisol Secretion (ACS)|ACTH-Independent Cushing Syndrome|ACTH-Independent Adrenal Cushing Syndrome, Somatic
DRUG: SPI-62 dose
Change in HbA1c at Week 6, HbA1c change from baseline, Baseline to week 6|Change in HbA1c at week 12, HbA1c change from baseline, Baseline to week 12
This is a multicenter, open-label, single-arm study, Phase 2 study to estimate SPI-62's effect on clinical features of hypercortisolism related to a benign adrenal tumor, including diabetes/impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period and an open-ended treatment period. Visits occur at screening/baseline, months 1, 3, 6, 9, and 12, and then quarter-annually.